We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Targovax AS (TRVX) NOK0.1

Sell:1.49 NOK Buy:1.60 NOK Change: 0.028 NOK (1.85%)
Market closed |  Prices as at close on 20 May 2022 | Switch to live prices |
Sell:1.49 NOK
Buy:1.60 NOK
Change: 0.028 NOK (1.85%)
Market closed |  Prices as at close on 20 May 2022 | Switch to live prices |
Sell:1.49 NOK
Buy:1.60 NOK
Change: 0.028 NOK (1.85%)
Market closed |  Prices as at close on 20 May 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Targovax ASA is a Norway-based company active within the healthcare sector. The Company is developing two complementary and targeted approaches in immuno-oncology: a peptide-based immunotherapy platform for patients with RAS-mutated cancers and a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors. The Company's candidate, TG01, is a peptide vaccine that targets mutations in the RAS genes that are associated with cancer, and it is in a phase II clinical trial in pancreatic cancer. The Company's other RAS targeting immunotherapy, TG02 is developed for colorectal cancer treatment. The Company's adenoviral candidate, ONCOS-102 is developed for the treatment of solid tumors, such as melanoma as well as ovarian and prostate cancer.

Contact details

Vollsveien 19
+47 (2) 1398810

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
285.27 million NOK
Shares in issue:
188.33 million
Oslo Stock Exchange
Norwegian Krone
Oslo All Share Index

Key personnel

  • Patrick Vink
    Chairman of the Board
  • Erik Digman Wiklund
    Chief Executive Officer
  • Lubor Gaal
    Chief Financial Officer
  • Jon Eriksen
    Chief Operating Officer
  • Antti Vuolanto
    Executive Vice President
  • Victor Levitsky
    Chief Scientific Officer
  • Anne Aksnes
    Vice President, Clinical Development
  • Tina Madsen
    Vice President, Quality Assurance
  • Peter Skorpil
    Vice President, Business Development
  • Nikolaj Knudtzon
    Head of HR

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.